Biohaven Ltd. will present an investor presentation detailing its ongoing and planned trials for various development programs, including troriluzole, taldefgrobep ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

In addition to TD Cowen, Biohaven Ltd. also received a Buy from William Blair’s Myles Minter in a report issued today. However, yesterday, RBC Capital maintained a Hold rating on Biohaven Ltd. (NYSE: ...

May 29, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. ( BHVN – Research Report) today and set a price target of $63.00. The company’s shares opened today at $15.43.

Completed U.S. Food and Drug Administration ("FDA") mid-cycle review meeting and regulatory inspections of Biohaven and key clinical research sites for troriluzole new drug application ("NDA") for ...

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with ...